Advertisement

Infektionen

  • H.-M. Lorenz
  • C. KneitzEmail author
Leitthema
  • 65 Downloads

Zusammenfassung

Die Einschätzung des Infektionsrisikos von Patienten mit rheumatologischen Erkrankungen basiert auf der sorgfältigen Erfassung der hierfür relevanten Faktoren wie der Grunderkrankung selbst, der Intensität der immunsuppressiven Therapie und der Schwere etwaiger Komorbiditäten. Aus infektiologischer Sicht sind hier besonders das wiederholte Auftreten schwerer Infektionen sowie Vorerkrankungen wie eine latente Tuberkulose oder eine chronische Hepatitis B oder C zu erwähnen. Dies kann eine prophylaktische antibiotische Therapie erforderlich machen, die ansonsten vermieden werden sollte, um nicht auf resistente Erreger zu selektionieren. Weiterhin sind Impfungen besonders geeignet das Risiko für häufige Infektionskrankheiten spezifisch zu minimieren.

Schlüsselwörter

Rheumatologische Erkrankungen Immunsuppression Vorerkrankungen Impfungen Prophylaktische Therapie 

Infections

Abstract

The individual risk assessment concerning infections in patients with rheumatic diseases is based on the detailed personalized documentation of relevant risk factors, such as the underlying disease itself, the intensity of immunosuppressive therapy and the severity of any comorbidities. From the perspective of infectiology, the history of repeated and severe infections as well as previous illnesses, such as (latent) tuberculosis and chronic hepatitis B or C need to be considered. In some instances prophylactic antibiotic therapy might be required, which should otherwise be avoided in order to prevent selection of resistant pathogens. Furthermore, vaccinations are particularly suitable to specifically minimize the risk for frequent infectious diseases.

Keywords

Rheumatic diseases Immunosuppression Pre-existing diseases Vaccination Prophylactic treatment 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

H.-M. Lorenz und C. Kneitz geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Gavazzi G, Krause KH (2002) Ageing and infection. Lancet Infect Dis 2(11):659–666 (Nov)CrossRefGoogle Scholar
  2. 2.
    Widdifield J, Bernatsky S, Paterson JM, Gunraj N, Thorne JC, Pope J, Cividino A, Bombardier C (2013) Arthritis Care Res 65(3):353–361CrossRefGoogle Scholar
  3. 3.
    Reber AJ, Kim JH, Biber R, Talbot HK, Coleman LA, Chirkova T, Gross FL, Steward-Clark E, Cao W, Jefferson S, Veguilla V, Gillis E, Meece J, Bai Y, Tatum H, Hancock K, Stevens J, Spencer S, Chen J, Gargiullo P, Braun E, Griffin MR, Sundaram M, Belongia EA, Shay DK, Katz JM, Sambhara S (2015) Preexisting Immunity, More Than Aging, Influences Influenza Vaccine Responses. Open Forum Infect Dis 15;2(2):ofv52 (Apr)Google Scholar
  4. 4.
    Reber AJ, Chirkova T, Kim JH, Cao W, Biber R, Shay DK, Sambhara S (2012) Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population. Aging Dis 3(1):68–90 (Epub 2011 Sep 30.)PubMedGoogle Scholar
  5. 5.
    Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46(9):2294–2300 (Sep)CrossRefGoogle Scholar
  6. 6.
    Hellmich B (2017) Current guidelines on ANCA-associated vasculitides: Common features and differences. Z Rheumatol 76(2):133–142CrossRefGoogle Scholar
  7. 7.
    Winthrop KL, Baddley JW (2018) Pneumocystis and glucocorticoid use: to prophylax or not to prophylax (and when?); that is the question. Ann Rheum Dis 77(5):631–633CrossRefGoogle Scholar
  8. 8.
    Baradat C et al (2017) RMD Open 3:E352CrossRefGoogle Scholar
  9. 9.
    Liao H et al (2017) Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. Int J Rheum Dis 20:161–168CrossRefGoogle Scholar
  10. 10.
    Dixon WG et al (2011) Annals Rheum Dis 70:956–996CrossRefGoogle Scholar
  11. 11.
    Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Watson KD, Lunt M (2011) BSRBR Control Centre Consortium, Symmons DP; British Society for Rheumatology Biologics Register. The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 50(7):1341–1342CrossRefGoogle Scholar
  12. 12.
    Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB (2018) Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Baillieres Clin Rheumatol 57(6):997–1001Google Scholar
  13. 13.
    Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA (2007) The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 57(8):1431–1438 (Dec 15)CrossRefGoogle Scholar
  14. 14.
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301(7):737–744 (Feb 18)CrossRefGoogle Scholar
  15. 15.
    Kivitz AJ, Cohen S, Keystone E, van Vollenhoven RF, Haraoui B, Kaine J, Fan H, Connell CA, Bananis E, Takiya L, Fleischmann R (2018) A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. Semin Arthritis Rheum.  https://doi.org/10.1016/j.semarthrit.2018.07.006 (Jul 19. pii: S0049-0172(17)30815-6, Epub ahead of print)CrossRefPubMedGoogle Scholar
  16. 16.
    Kunwar S, Collins CE, Constantinescu F (2018) Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials. Clin Rheumatol.  https://doi.org/10.1007/s10067-018-4199-7 (Jul 13)CrossRefPubMedGoogle Scholar
  17. 17.
    Droz N, Gilardin L, Cacoub P, Berenbaum F, Wendling D, Godeau B, Piette AM, Dernis E, Ebbo M, Fautrel B, Le Guenno G, Mekinian A, Bernard-Chabert B, Costedoat-Chalumeau N, Descloux E, Michot JM, Radenne S, Rigolet A, Rivière S, Yvin JL, Thibault V, Thabut D, Pol S, Guillevin L, Mouthon L, Terrier B (2013) Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases. Arthritis Care Res (hoboken) 65(9):1504–1514 (Sep)CrossRefGoogle Scholar
  18. 18.
    Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Obeng Baah J, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata RC, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion MJ, Li PZ, Hill PC, Schwartzman K, Benedetti A (2018) Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med 379(5):440–453CrossRefGoogle Scholar
  19. 19.
    Liao H, Zhong Z, Liu Z, Zou X (2017) Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. Int J Rheum Dis 20(2):161–168CrossRefGoogle Scholar
  20. 20.
    Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D (2017) Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Ther Clin Risk Manag 14:2097–2111Google Scholar
  21. 21.
    Bartalesi F, Scirè C, Requena-Méndez A et al (2017) Recommendations for infectious disease screening in migrants to Western Europe with inflammatory arthropathies before starting biologic agents. Results from a multidisciplinary task force of four European societies (SIR, SER, SIMET, SEMTSI) facing the largest impact of the flow of migrants today. Clin Exp Rheumatol 35(5):752–765 (Sep–Oct; Epub  2017 May 8)PubMedGoogle Scholar
  22. 22.
    Epidemiologisches Bulletin 34/2018Google Scholar
  23. 23.
    Nguyen MTT, Lindegaard H, Hendricks O, Jørgensen CS, Kantsø B, Friis-Møller N (2017) Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial. J Rheumatol 44(12):1794–1803CrossRefGoogle Scholar
  24. 24.
    Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, Kozuru H, Jiuchi Y, Matsumura R, Suematsu E, Miyamura T, Mori S, Fukui T, Izumi Y, Iwanaga N, Tsutani H, Saisyo K, Yamanaka T, Ohshima S, Mori N, Matsumori A, Takahi K, Yoshizawa S, Kawabe Y, Suenaga Y, Ozawa T, Hamada N, Komiya Y, Matsui T, Furukawa H, Oishi K (2015) Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients. Arthritis Res Ther 10;17:357 (Dec)CrossRefGoogle Scholar
  25. 25.
    Park JK, Lee YJ, Shin K et al (2018) Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis 77(6):898–904PubMedPubMedCentralGoogle Scholar
  26. 26.
    Epidemiologisches Bulletin 36/37 vom 9. Sept. 2013Google Scholar
  27. 27.
    Feuchtenberger M, Kleinert S, Schwab S, Roll P, Scharbatke EC, Ostermeier E, Voll RE, Schäfer A, Tony HP (2012) Vaccination survey in patients with rheumatoid arthritis: a cross-sectional study. Rheumatol Int 32(6):1533–1539 (Jun)CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Medizinische Universitätsklinik V: Hämatologie, Onkologie, RheumatologieUniversitätsklinikum HeidelbergHeidelbergDeutschland
  2. 2.ACURA Rheumazentrum Baden-BadenBaden-BadenDeutschland
  3. 3.Rheumatologische Facharztpraxis SchwerinSchwerinDeutschland

Personalised recommendations